Andreev Konstantin, Jones Jeremy C, Seiler Patrick, Kandeil Ahmed, Turner Jasmine C M, Barman Subrata, Rubrum Adam M, Webby Richard J, Govorkova Elena A
Department of Host-Microbe Interactions, St. Jude Children's Research Hospital, Memphis, Tennessee.
J Infect Dis. 2024 Jun 14;229(6):1830-1835. doi: 10.1093/infdis/jiad418.
The antiviral susceptibility of currently circulating (2022-2023) highly pathogenic avian influenza (HPAI) A(H5N1) viruses was assessed by genotypic and phenotypic approaches. The frequency was low for neuraminidase (NA) and polymerase acidic (PA) substitutions associated with reduced inhibition by NA inhibitors (21/2698, 0.78%) or the PA inhibitor baloxavir (14/2600, 0.54%). Phenotypic testing of 22 clade 2.3.2.1a and 2.3.4.4b viruses revealed broad susceptibility to NA inhibitors and baloxavir for a conclusion that most contemporary HPAI A(H5N1) viruses retain susceptibility to antiviral drugs. Novel NA-K432E and NA-T438I substitutions (N2 numbering) were identified at elevated frequencies (104/2698, 3.85%) and caused reduced zanamivir and peramivir inhibition.
通过基因型和表型方法评估了当前流行的（2022 - 2023年）高致病性禽流感（HPAI）A(H5N1)病毒的抗病毒敏感性。与神经氨酸酶（NA）抑制剂抑制作用降低相关的NA和聚合酶酸性（PA）取代的频率较低（21/2698，0.78%），或PA抑制剂巴洛沙韦（14/2600，0.54%）。对22株2.3.2.1a和2.3.4.4b分支病毒的表型测试显示，它们对NA抑制剂和巴洛沙韦具有广泛的敏感性，由此得出结论，大多数当代HPAI A(H5N1)病毒仍对抗病毒药物敏感。新型NA-K432E和NA-T438I取代（N2编号）在较高频率（104/2698，3.85%）下被鉴定出来，并导致扎那米韦和帕拉米韦抑制作用降低。
